“TOZUDA came to my attention on LinkedIn as I have suffered a few concussions myself while playing football, hockey and downhill skiing in my past, said President, Scott Kadwell of RSK Medical Inc.. “I was also touched by the movie called “Concussion” depicting the findings of pathologist Dr. Bennett Omahu who brought the issue of brain damage to the forefront amongst NFL football players and the public domain. He discovered “Chronic Traumatic Encephalopathy” (CTE) in Pittsburgh Steeler players who had experienced repeated head blows which had terrible effects on their medical conditions and lifespan.

“It is easy for parents or coaches to assume players will not incur head injuries and some associations are afraid to acknowledge even the best protocols will not pick up all the head injuries due to the nature of the support and how hits impact people differently”. “Intentional or accidental hits are going to happen”. “It is important to have the “peace of mind” that the high impact hits will get checked out”. It is scientifically documented that 50% of head injuries go under diagnosed or undetected. In addition, 90% of diagnosed head injuries do not involve a loss of consciousness. Each additional hit is accumulative to causing further damage to the injured brain.

The TOZUDA Head Impact Sensor can be easily attached to hockey, snowboarding, snow-skiing, football, cycling and construction helmets to name a few. Please check out the www.tozuda.com website for further information or contact RSK Medical Inc. at generalinquiry@rskmedical.com

Please take note we also represent electroCore which manufactures a non-invasive Vagus Nerve Stimulator (nVNS) called the Sapphire for treatment of migraine and cluster headaches.

RSK Medical Inc. is pleased to announce a nationwide distribution agreement with Texray AB located in Kungsbacka, Sweden effective immediately.

Texray has invented the only radiation protection textile in the world.  Their unique material and product design can reduce scatter radiation towards the head and neck by up to 97% to enhance the safety of healthcare professionals.

The Texray product line can be used in interventional electrophysiology, cardiology, radiology and endovascular surgery procedures where RSK Medical already offers other specialty products.

We look forward to introducing the Texray radiation protection products across Canada.

ST. PAUL, Minn.–(BUSINESS WIRE)– Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Canada have been treated with its Diamondback 360®Coronary Orbital Atherectomy System (OAS).

The first patients in Canada were treated by Sanjog Kalra, MD, Interventional Cardiologist and Cardiac Critical Care Physician at the Peter Munk Cardiac Centre, Toronto General Hospital, part of the University Health Network.

Read more.

RSK Medical Inc. and Cardiovascular Systems Inc.(CSI), manufacturers of the proven Diamondback 360 orbital rotational atherectomy systems for peripheral and coronary use have signed an agent representation agreement for sales, marketing and clinical support across Canada. The Diamondback 360 offers a low profile (6Fr compatible) system for the radial or femoral approach. The system has a unique mechanism of action (MOA) using a combination of centrifugal force and differential sanding to safely and simply reduce arterial calcium to enable successful stent delivery. The two platforms have been fully approved by Health Canada and we look forward to launching Diamondback 360 over the next few months. Please see www.csi360.com for further product details and clinical data.

RSK Medical Inc. has signed a long term agreement (Canada-wide) to represent Angiodroid Srl from Bologna, Italy.

Angiodroid manufacturers The CO2 Injector, the first system for Automated Carbon Dioxide Angiography (ACDA) dedicated to diagnostic and interventional procedures in peripheral and venous systems.

The Safety and Efficacy of Angiodroid’s CO2 injector has been validated in over 20 international clinical studies to date. This technology makes it possible to use CO2, a 100% biocompatible gas to obtain high quality radiological angiographic images while preserving the renal function of the patients. The ACDA system system avoids all contrast induced nephropathy risks and potential for allergic reactions.

Angiodroid has begun preparation for submitting for Health Canada regulatory approval. Find more on www.angiodroid.com.